The diagnostic technology developer will use the funds secured in the Robert Bosch-led round to bring its laser-based lead product to market.
Germany-based diagnostic instrument maker GNA Biosolutions has raised €6m ($6.6m) in a series B round led by Robert Bosch Venture Capital (RBVC), the corporate venturing arm of industrial product manufacturer Robert Bosch.
The round also included venture capital firms SHS Gesellschaft für Beteiligungsmanagement, B-to-V Partners and UnternehmerTUM, investment firm Mey Capital Matrix and development bank KfW.
GNA will use the cash to support the advance of its lead product, Pharos400, to market. Pharos400 uses a laser to process diagnostic samples and provides real-time detection and quantification for users.
Dieter Kraft, investment partner at Robert Bosch Venture Capital, said: “With GNA Biosolutions, we are delighted to be supporting a company which operates at the interface between sophisticated mechatronic engineering and the growing global healthcare market, and one that has developed key innovations in this market.”
GNA was founded in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich. The company’s previous funding came from its founders, Mey Capital Matrix and KfW.
This article first appeared on our sister site Global Corporate Venturing.
